The Effect of α-GPC on Cognitive Function and Sports Performance
NCT07267845, Not applicable, Completed, Nanjing Nutrabuilding Bio-tech Co., Ltd.
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | The Effect of α-GPC on Cognitive Function and Sports Performance | ClinicalTrials.gov |
| NCT number | NCT07267845 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 81 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Nanjing Nutrabuilding Bio-tech Co., Ltd. | ClinicalTrials.gov |
| Conditions | Healthy Participants | ClinicalTrials.gov |
| Interventions | Alpha-Glycerophosphocholine（α-GPC）, Microcrystalline Cellulose (placebo) | ClinicalTrials.gov |
| First posted | 2025-12-05 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 34
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Cognitive Performance - Stroop Test-Stroop total score | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42） | Test the stroop total score change (Δ) of from Day 1 to Day 42 in the α-GPC group compared to placebo on Stroop Test. | ClinicalTrials.gov |
| Secondary | Cognitive Performance - Stroop Test - Stroop accuracy (%) | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42） | Test the stroop accuracy (%) change (Δ) of from Day 1 to Day 42 in the α-GPC group compared to placebo on Stroop Test. | ClinicalTrials.gov |
| Secondary | Cognitive Performance - Stroop Test - Stroop time per score (s) | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42） | Test the stroop time per score (s) change (Δ) of from Day 1 to Day 42 in the α-GPC group compared to placebo on Stroop Test. | ClinicalTrials.gov |
| Secondary | Cognitive performance - Digit-Symbol Substitution Test (DSST) - Number of Correct Symbols (N) | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42） | Test the Number of Correct Symbols (N) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. | ClinicalTrials.gov |
| Secondary | Cognitive performance - Digit-Symbol Substitution Test (DSST) - Total Correct Score | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42） | Test the Total Correct Score change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. | ClinicalTrials.gov |
| Secondary | Cognitive performance - Digit-Symbol Substitution Test (DSST) - Accuracy (%) | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42） | Test the Accuracy (%) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. | ClinicalTrials.gov |
| Secondary | Cognitive performance - Digit-Symbol Substitution Test (DSST) - Time per Correct Response (s/item) | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42） | Test the Time per Correct Response (s/item) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. | ClinicalTrials.gov |
| Secondary | Cognitive performance - Go/No-go Test - Correct responses (N) | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）. | Test the Go/No-Go - Correct responses (N) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. | ClinicalTrials.gov |
| Secondary | Cognitive performance - Go/No-go Test - Errors of omissions (%) | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）. | Test the Go/No-Go - Errors of omissions (%) change (Δ) from Day 1 to Day 42 effect in the α-GPC group compared to placebo. | ClinicalTrials.gov |
| Secondary | Cognitive performance - Go/No-go Test - Errors of commission (%) | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）. | Test the Go/No-Go - Errors of commission (%) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. | ClinicalTrials.gov |
| Secondary | Cognitive performance - Go/No-go Test - Correct rejections (N) | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）. | Test the Go/No-Go - Correct rejections (N) change (Δ) from Day 1 to Day 42 effect in the α-GPC group compared to placebo. | ClinicalTrials.gov |
| Secondary | Cognitive performance - Go/No-go Test - Mean response times (mins) | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）. | Test the Go/No-Go - Mean response times (mins) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. | ClinicalTrials.gov |
| Secondary | Cognitive performance - Go/No-go Test - Reaction time (mins) | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）. | Test the Reaction time (mins) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. | ClinicalTrials.gov |
| Secondary | Cognitive performance - Go/No-go Test- Reaction time variability (RTV) | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）. | Test the Reaction time variability (RTV) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. | ClinicalTrials.gov |
| Secondary | Cognitive Performance - Sustained Attention to Response Task (SART) - Total Commission Errors (N) | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42） | Test total commission errors (N) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. | ClinicalTrials.gov |
| Secondary | Cognitive Performance - Sustained Attention to Response Task (SART) - Omission Errors (N) | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42） | Test omission errors (N) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. | ClinicalTrials.gov |
| Secondary | Cognitive Performance - Sustained Attention to Response Task (SART) - Reaction Time (Mean RT) | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42） | Test reaction time (Mean RT) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo. | ClinicalTrials.gov |
| Secondary | Cognitive Performance - Sustained Attention to Response Task (SART) - Reaction Time Variability (RTV) | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42） | Test reaction time variability (RTV) change (Δ) from Day 1 to Day 42 effect in the α-GPC group compared to placebo on. | ClinicalTrials.gov |
| Secondary | Upper Body Power - Average power (W) | Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）. | The average power (W) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to the Placebo group will be assessed by Ballistic Smith Machine Bench Press. | ClinicalTrials.gov |
| Secondary | Upper Body Power - Peak power production (W) | Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）. | The peak power production (W) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to the Placebo group will be assessed by Ballistic Smith Machine Bench Press. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 3
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Go/No-Go Task | Secondary outcome | ConductCognition |
| Sustained Attention to Response | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)